Please try another search
Cantabio Pharmaceuticals Inc. is a preclinical stage biotechnology company. The Company is focused on commercializing therapies and the intellectual property generated from its research and development activities for Parkinson’s disease (PD), Alzheimer’s disease (AD) and other related neurodegenerative diseases. The Company’s small molecule therapy candidates program (CB101) and protein therapy candidate (CB201) targets Parkinson’s disease and a range of neurodegenerative diseases including Alzheimer’s disease, amyotrophic lateral sclerosis (ALS), Huntington’s disease and stroke. It also has two additional small molecule pharmacological chaperone programs for the treatment of Alzheimer’s Disease (and other related dementias); CB301, targeting the Tau protein, for the development of Alzheimer’s therapeutics, and CB401, targeting the Aß peptide in Alzheimer’s drug research. The Company’s strategy integrates therapeutic focus on targeting family biophysics and drug discovery technology.
Name | Age | Since | Title |
---|---|---|---|
Franklin Aigbirhio | - | - | Member of Scientific Advisory Board |
Lisa McConlogue | - | - | Member of Scientific Advisory Board |
Peter H. St George Hyslop | - | - | Member of Scientific Advisory Board |
Jean-Christophe Rochet | - | - | Member of Scientific Advisory Board |
Thomas Roger Sawyer | 51 | 2019 | CFO & Director |
Johnny He | - | 2019 | Director |
Gergely Toth | 47 | 2009 | Founder, CEO, President & Director |
Max Zhu | 39 | 2015 | Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review